Visus Therapeutics Signs an Exclusive License Agreement with Zhaoke to Develop & Commercialize Brimochol PF and Carbachol PF for Presbyopia
Shots:
- Visus to receive $15M up front, ~$115M in milestones along with royalties in licensed territories. ZKO will lead the clinical development, regulatory approval & commercialization activities for Brimochol PF & Carbachol PF in the territories
- ZKO will use its clinical development experience while Visus supports the ongoing P-III studies & launch the product in Greater China, South Korea & selected Southeast Asian markets
- ZKO continues to expand its pipeline of ophthalmic assets & has clinical development plans including NDA submission to CDE in China for CsA Ophthalmic Gel, continuing patient recruitment in P-III study of NVK002 for myopia & launched a clinical study in China for presbyopia
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
